Patrick O'Brien, COO and General Counsel at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 33,860 shares at $38.58 ($1.3M) on 2023-01-03, disclosed to the SEC on 2023-01-05.
Seasonal sale ($1.3M) by COO and General Counsel — this insider has traded ARWR in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $37.53 | 2,653 | $100K | 7.7% |
| 2 | $37.53 | 2,653 | $100K | 7.7% |
| 3 | $37.58 | 2,894 | $109K | 8.4% |
| 4 | $37.58 | 2,894 | $109K | 8.4% |
| 5 | $38.54 | 5,527 | $213K | 16.4% |
| 6 | $38.54 | 5,527 |
| $213K |
| 16.4% |
| 7 | $38.58 | 5,286 | $204K | 15.7% |
| 8 | $38.58 | 5,286 | $204K | 15.7% |
| 9 | $39.55 | 300 | $12K | 0.9% |
| 10 | $39.74 | 500 | $20K | 1.5% |
| 11 | $40.53 | 270 | $11K | 0.8% |
| 12 | $40.80 | 70 | $3K | 0.2% |
| Total | $38.28 avg | 33,860 | $1.3M | 100% |
| Filing → |
| GLRE | SELL | 2025-05-14 | $267K | — | Filing → |
| ARWR | SELL | 2025-01-07 | $1.3M | — | Filing → |
| ARWR | SELL | 2024-01-05 | $1.9M | — | Filing → |